{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T03:52:35Z","timestamp":1792641155876,"version":"4.5.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"DOI":"10.1007\/s12029-025-01384-9","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T04:25:25Z","timestamp":1777523125000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["MET Amplification in Gallbladder Cancer: a Case Report on a Precision Medicine Approach with Glumetinib and Envafolimab"],"prefix":"10.1007","volume":"57","author":[{"given":"Xiao-Jie","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Fan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren-Jie","family":"Gui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua-Xin","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,30]]},"reference":[{"issue":"1","key":"1384_CR1","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41572-022-00398-y","volume":"8","author":"JC Roa","year":"2022","unstructured":"Roa JC, Garc\u00eda P, Kapoor VK, Maithel SK, Javle M, Koshiol J. Gallbladder cancer. Nat Reviews Disease Primers. 2022;8(1):69. https:\/\/doi.org\/10.1038\/s41572-022-00398-y.","journal-title":"Nat Reviews Disease Primers"},{"issue":"1","key":"1384_CR2","doi-asserted-by":"publisher","first-page":"3122","DOI":"10.1186\/s12889-024-20584-9","volume":"24","author":"X Zhang","year":"2024","unstructured":"Zhang X, Xu C, Zhang H, Du X, Zhang Q, Lu M, Ma Y, Ma W. Gallbladder cancer incidence and mortality rate trends in china: analysis of data from the population-based cancer registry. BMC Public Health. 2024;24(1):3122. https:\/\/doi.org\/10.1186\/s12889-024-20584-9.","journal-title":"BMC Public Health"},{"issue":"5","key":"1384_CR3","doi-asserted-by":"publisher","first-page":"474","DOI":"10.21147\/j.issn.1000-9604.2024.05.02","volume":"36","author":"J Zhou","year":"2024","unstructured":"Zhou J, Tan G, Zhang L, Xie G, Chen W, Zhang X, Liang H. Epidemiology of biliary tract cancer in china: A narrative review. Chin J Cancer Res = Chung-kuo Yen Cheng Yen Chiu. 2024;36(5):474\u201388. https:\/\/doi.org\/10.21147\/j.issn.1000-9604.2024.05.02.","journal-title":"Chin J Cancer Res = Chung-kuo Yen Cheng Yen Chiu"},{"key":"1384_CR4","doi-asserted-by":"publisher","unstructured":"Piovani D, Nikolopoulos GK, Aghemo A, Lleo A, Alqahtani SA, Hassan C, Repici A, Bonovas S. Environmental risk factors for gallbladder cancer: Field-Wide systematic review and Meta-Analysis. Clin Gastroenterol Hepatol: Off Clin Pract J Am Gastroenterol Assoc. 2024;S1542-3565(24):00866-8. Advance online publication. https:\/\/doi.org\/10.1016\/j.cgh.2024.07.046.","DOI":"10.1016\/j.cgh.2024.07.046"},{"issue":"4","key":"1384_CR5","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1038\/sj.bjc.6605211","volume":"101","author":"JW Valle","year":"2009","unstructured":"Valle JW, Wasan H, Johnson P, Jones E, Dixon L, Swindell R, Baka S, Maraveyas A, Corrie P, Falk S, Gollins S, Lofts F, Evans L, Meyer T, Anthoney A, Iveson T, Highley M, Osborne R, Bridgewater J. Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study - The UK ABC-01 study. Br J Cancer. 2009;101(4):621\u20137. https:\/\/doi.org\/10.1038\/sj.bjc.6605211.","journal-title":"Br J Cancer"},{"issue":"3","key":"1384_CR6","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1002\/hep.31088","volume":"72","author":"E Lozano","year":"2020","unstructured":"Lozano E, Asensio M, Perez-Silva L, Banales JM, Briz O, Marin JJG. MRP3-Mediated chemoresistance in cholangiocarcinoma: target for chemosensitization through restoring SOX17 expression. Hepatology (Baltimore MD). 2020;72(3):949\u201364. https:\/\/doi.org\/10.1002\/hep.31088.","journal-title":"Hepatology (Baltimore MD)"},{"key":"1384_CR7","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.semcancer.2022.12.004","volume":"88","author":"GP Nagaraju","year":"2023","unstructured":"Nagaraju GP, Farran B, Luong T, El-Rayes BF. Understanding the molecular mechanisms that regulate pancreatic cancer stem cell formation, stemness and chemoresistance: A brief overview. Sem Cancer Biol. 2023;88:67\u201380. https:\/\/doi.org\/10.1016\/j.semcancer.2022.12.004.","journal-title":"Sem Cancer Biol"},{"issue":"3","key":"1384_CR8","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1016\/j.apsb.2022.10.002","volume":"13","author":"L Zhang","year":"2023","unstructured":"Zhang L, Ye B, Chen Z, Chen ZS. Progress in the studies on the molecular mechanisms associated with multidrug resistance in cancers. Acta Pharm Sinica B. 2023;13(3):982\u201397. https:\/\/doi.org\/10.1016\/j.apsb.2022.10.002.","journal-title":"Acta Pharm Sinica B"},{"issue":"14","key":"1384_CR9","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, Roughton M, Bridgewater J. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273\u201381. https:\/\/doi.org\/10.1056\/NEJMoa0908721. & ABC-02 Trial Investigators","journal-title":"N Engl J Med"},{"key":"1384_CR10","doi-asserted-by":"publisher","first-page":"1183619","DOI":"10.3389\/fphar.2023.1183619","volume":"14","author":"Y Zhou","year":"2023","unstructured":"Zhou Y, Yuan K, Yang Y, Ji Z, Zhou D, Ouyang J, Wang Z, Wang F, Liu C, Li Q, Zhang Q, Li Q, Shan X, Zhou J. Gallbladder cancer: current and future treatment options. Front Pharmacol. 2023;14:1183619. https:\/\/doi.org\/10.3389\/fphar.2023.1183619.","journal-title":"Front Pharmacol"},{"key":"1384_CR11","doi-asserted-by":"publisher","unstructured":"Xu Y, Kong W, Cao M, Wang J, Wang Z, Zheng L, Wu X, Cheng R, He W,Yang B, Dong B, Pan J, Chen Y, Huang J, Jiang C, Zhai W, Li F, Chen R, Zhou X, Wu G, \u2026 Xue W. Genomic Profiling and response to immune checkpoint inhibition plus tyrosine kinase inhibition in FH-deficient renal cell carcinoma. Eur Urol. 2023;83(2):163\u2013172. https:\/\/doi.org\/10.1016\/j.eururo.2022.05.029.","DOI":"10.1016\/j.eururo.2022.05.029"},{"issue":"11","key":"1384_CR12","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/s41571-023-00812-8","volume":"20","author":"D Killock","year":"2023","unstructured":"Killock D. Novel ICI-TKI combination improves HCC outcomes. Nature reviews. Clin Oncol. 2023;20(11):733. https:\/\/doi.org\/10.1038\/s41571-023-00812-8.","journal-title":"Clin Oncol"},{"key":"1384_CR13","doi-asserted-by":"publisher","first-page":"108499","DOI":"10.1016\/j.pharmthera.2023.108499","volume":"249","author":"M Catalano","year":"2023","unstructured":"Catalano M, Procopio G, Sepe P, Santoni M, Sessa F, Villari D, Nesi G, Roviello G. Tyrosine kinase and immune checkpoints inhibitors in favorable risk metastatic renal cell carcinoma: trick or treat? Pharmacol Ther. 2023;249:108499. https:\/\/doi.org\/10.1016\/j.pharmthera.2023.108499.","journal-title":"Pharmacol Ther"},{"issue":"12","key":"1384_CR14","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s00262-024-03841-z","volume":"73","author":"S Wang","year":"2024","unstructured":"Wang S, Chao J, Wang H, Li S, Wang Y, Zhu C, Zhang N, Piao M, Yang X, Liu K, Xun Z, Sang X, Yang X, Duan W, Zhao H. Effectiveness, safety, and biomarker analysis of lenvatinib plus Toripalimab as chemo-free therapy in advanced intrahepatic cholangiocarcinoma: a real-world study. Cancer Immunol Immunotherapy: CII. 2024;73(12):249. https:\/\/doi.org\/10.1007\/s00262-024-03841-z.","journal-title":"Cancer Immunol Immunotherapy: CII"},{"key":"1384_CR15","doi-asserted-by":"publisher","first-page":"946861","DOI":"10.3389\/fimmu.2022.946861","volume":"13","author":"C Shi","year":"2022","unstructured":"Shi C, Li Y, Yang C, Qiao L, Tang L, Zheng Y, Chen X, Qian Y, Yang J, Wu D, Xie F. Lenvatinib plus programmed cell death Protein-1 inhibitor beyond First-Line systemic therapy in refractory advanced biliary tract cancer: A Real-World retrospective study in China. Front Immunol. 2022;13:946861. https:\/\/doi.org\/10.3389\/fimmu.2022.946861.","journal-title":"Front Immunol"},{"issue":"1","key":"1384_CR16","doi-asserted-by":"publisher","first-page":"188391","DOI":"10.1016\/j.bbcan.2020.188391","volume":"1874","author":"Y Zhao","year":"2020","unstructured":"Zhao Y, Zhang YN, Wang KT, Chen L. Lenvatinib for hepatocellular carcinoma: from preclinical mechanisms to anti-cancer therapy. Biochimica et biophysica acta. Reviews Cancer. 2020;1874(1):188391. https:\/\/doi.org\/10.1016\/j.bbcan.2020.188391.","journal-title":"Reviews Cancer"},{"key":"1384_CR17","doi-asserted-by":"publisher","unstructured":"Yu Y, Zhou J, Li X, Goto K, Min X, Nishino K, Cui J, Wu L, Sakakibara J, Shu Y, Dong X, Li L, Yoneshima Y, Zhou C, Li X, Zhang Y, Huang D, Zang A, Zhang W, Wang X, \u2026 Lu S. Gumarontinib in patients with non-small-cell lung cancer harbouring MET exon 14 skipping mutations: a multicentre,single-arm, open-label, phase 1b\/2 trial. EClinicalMedicine. 2023;59:101952. https:\/\/doi.org\/10.1016\/j.eclinm.2023.101952.","DOI":"10.1016\/j.eclinm.2023.101952"},{"issue":"1","key":"1384_CR18","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s10555-007-9107-6","volume":"27","author":"A Gentile","year":"2008","unstructured":"Gentile A, Trusolino L, Comoglio PM. The Met tyrosine kinase receptor in development and cancer. Cancer Metastasis Rev. 2008;27(1):85\u201394. https:\/\/doi.org\/10.1007\/s10555-007-9107-6.","journal-title":"Cancer Metastasis Rev"},{"issue":"4","key":"1384_CR19","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1158\/1535-7163.MCT-17-0368","volume":"17","author":"J Ai","year":"2018","unstructured":"Ai J, Chen Y, Peng X, Ji Y, Xi Y, Shen Y, Yang X, Su Y, Sun Y, Gao Y, Ma Y, Xiong B, Shen J, Ding J, Geng M. Preclinical evaluation of SCC244 (Glumetinib), a Novel, Potent, and highly selective inhibitor of c-Met in MET-dependent cancer models. Mol Cancer Ther. 2018;17(4):751\u201362. https:\/\/doi.org\/10.1158\/1535-7163.MCT-17-0368.","journal-title":"Mol Cancer Ther"},{"issue":"6","key":"1384_CR20","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1053\/j.gastro.2019.01.252","volume":"156","author":"H Li","year":"2019","unstructured":"Li H, Li CW, Li X, Ding Q, Guo L, Liu S, Liu C, Lai CC, Hsu JM, Dong Q, Xia W, Hsu JL, Yamaguchi H, Du Y, Lai YJ, Sun X, Koller PB, Ye Q, Hung MC. MET inhibitors promote liver tumor evasion of the immune response by stabilizing PDL1. Gastroenterology. 2019;156(6):1849\u2013e186113. https:\/\/doi.org\/10.1053\/j.gastro.2019.01.252.","journal-title":"Gastroenterology"},{"issue":"18","key":"1384_CR21","doi-asserted-by":"publisher","first-page":"4579","DOI":"10.1158\/1078-0432.CCR-18-0267","volume":"24","author":"M Saigi","year":"2018","unstructured":"Saigi M, Alburquerque-Bejar JJ, Leer-Florin M, Pereira A, Pros C, Romero E, Baixeras OA, Esteve-Codina N, Nadal A, Brambilla E, E., Sanchez-Cespedes M. MET-Oncogenic and JAK2-Inactivating alterations are independent factors that affect regulation of PD-L1 expression in lung cancer. Clin Cancer Research: Official J Am Association Cancer Res. 2018;24(18):4579\u201387. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-0267.","journal-title":"Clin Cancer Research: Official J Am Association Cancer Res"},{"issue":"1","key":"1384_CR22","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s12943-019-1073-4","volume":"18","author":"S Peng","year":"2019","unstructured":"Peng S, Wang R, Zhang X, Ma Y, Zhong L, Li K, Nishiyama A, Arai S, Yano S, Wang W. EGFR-TKI resistance promotes immune escape in lung cancer via increased PD-L1 expression. Mol Cancer. 2019;18(1):165. https:\/\/doi.org\/10.1186\/s12943-019-1073-4.","journal-title":"Mol Cancer"},{"issue":"2","key":"1384_CR23","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.canlet.2015.11.013","volume":"370","author":"SR Martins-Neves","year":"2016","unstructured":"Martins-Neves SR, Paiva-Oliveira DI, Wijers-Koster PM, Abrunhosa AJ, Fontes-Ribeiro C, Bov\u00e9e JV, Cleton-Jansen AM, Gomes CM. Chemotherapy induces stemness in osteosarcoma cells through activation of Wnt\/\u03b2-catenin signaling. Cancer Lett. 2016;370(2):286\u201395. https:\/\/doi.org\/10.1016\/j.canlet.2015.11.013.","journal-title":"Cancer Lett"},{"issue":"9","key":"1384_CR24","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1136\/gutjnl-2023-331773","volume":"73","author":"H He","year":"2024","unstructured":"He H, Chen S, Yu Y, Fan Z, Qian Y, Dong Y, Song Y, Zhong C, Sun X, Cao Q, Li S, Huang W, Li W, Zhuang M, Yang J, Wang X, Wang J, Wu D, Wang H, Wen W. Comprehensive single-cell analysis Deciphered microenvironmental dynamics and immune regulator Olfactomedin 4 in pathogenesis of gallbladder cancer. Gut. 2024;73(9):1529\u201342. https:\/\/doi.org\/10.1136\/gutjnl-2023-331773.","journal-title":"Gut"},{"key":"1384_CR25","doi-asserted-by":"publisher","unstructured":"Li M, Liu F, Zhang F, Zhou W, Jiang X, Yang Y, Qu K, Wang Y, Ma Q, Wang T, Bai L, Wang Z, Song X, Zhu Y, Yuan R, Gao Y, Liu Y, Jin Y, Li H, Xiang S, \u2026 Liu Y. Genomic ERBB2\/ERBB3 mutations promote PD-L1-mediated immune escape in gallbladder cancer: a whole-exome sequencing analysis. Gut. 2019;68(6):1024\u20131033. https:\/\/doi.org\/10.1136\/gutjnl-2018-316039.","DOI":"10.1136\/gutjnl-2018-316039"},{"key":"1384_CR26","doi-asserted-by":"publisher","unstructured":"Oh DY, He AR, Bouattour M, Okusaka T, Qin S, Chen LT, Kitano M, Lee CK, Kim JW, Chen MH, Suksombooncharoen T, Ikeda M, Lee MA, Chen JS, Potemski P, Burris HA 3rd, Ostwal V, Tanasanvimon S, Morizane C, Zaucha RE, \u2026 Valle JW. Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study. The lancet. Gastroenterol Hepatol. 2024;9(8):694\u2013704. https:\/\/doi.org\/10.1016\/j.metabol.2012.08.016","DOI":"10.1016\/j.metabol.2012.08.016"},{"issue":"1","key":"1384_CR27","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S1470-2045(24)00649-1","volume":"26","author":"TK Choueiri","year":"2025","unstructured":"Choueiri TK, Merchan JR, Figlin R, McDermott DF, Arrowsmith E, Michaelson MD, Tykodi SS, Heath EI, Spigel DR, Souza D, Kassalow A, Perini L, Vickery RF, D., Bauer TM. Belzutifan plus Cabozantinib as first-line treatment for patients with advanced clear-cell renal cell carcinoma (LITESPARK-003): an open-label, single-arm, phase 2 study. Lancet Oncol. 2025;26(1):64\u201373. https:\/\/doi.org\/10.1016\/S1470-2045(24)00649-1.","journal-title":"Lancet Oncol"},{"issue":"Suppl 1","key":"1384_CR28","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1016\/j.metabol.2012.08.016","volume":"62","author":"M Kalia","year":"2013","unstructured":"Kalia M. Personalized oncology: recent advances and future challenges. Metab Clin Exp. 2013;62(Suppl 1):S11\u20134. https:\/\/doi.org\/10.1016\/j.metabol.2012.08.016.","journal-title":"Metab Clin Exp"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-025-01384-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-025-01384-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-025-01384-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T04:25:27Z","timestamp":1777523127000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-025-01384-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,30]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1384"],"URL":"https:\/\/doi.org\/10.1007\/s12029-025-01384-9","relation":{},"ISSN":["1941-6636"],"issn-type":[{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,30]]},"assertion":[{"value":"20 December 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The participant has consented to the submission of the case report to the journal. Written informed consent was obtained from the patient for publication of the details of his medical case and any accompanying images.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"CARE Checklist (2016) Statement"}},{"value":"Unsolicited article; Externally peer reviewed.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Provenance and Peer Review"}},{"value":"Single blind","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Peer-Review Model"}},{"value":"None.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Corresponding Author's Membership in Professional Societies"}}],"article-number":"103"}}